MED Medifast Forecast, Technical & Fundamental Analysis

MED's RSI Indicator peaks and leaves overbought zone

The 10-day RSI Indicator for MED moved out of overbought territory on September 03, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 14 instances where the indicator moved out of the overbought zone. In 14 of the 14 cases the stock moved lower in the days that followed. This puts the odds of a move down at 90%.

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on September 28, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MED as a result. In 82 of 95 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 86%.

The Moving Average Convergence Divergence Histogram (MACD) for MED turned negative on September 09, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 57 similar instances when the indicator turned negative. In 49 of the 57 cases the stock turned lower in the days that followed. This puts the odds of success at 86%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where MED declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.

The Aroon Indicator for MED entered a downward trend on October 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

MED moved above its 50-day moving average on October 02, 2026 date and that indicates a change from a downward trend to an upward trend.

The 50-day moving average for MED moved above the 200-day moving average on September 08, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

MED may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 2 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 39 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.667) is normal, around the industry mean (7.520). MED's P/E Ratio (531.500) is considerably higher than the industry average of (51.365). Projected Growth (PEG Ratio) (0.230) is also within normal values, averaging (4.440). MED's Dividend Yield (0.089) is considerably higher than the industry average of (0.019). P/S Ratio (0.416) is also within normal values, averaging (1.645).

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is 54 (best 1 - 100 worst), indicating steady price growth. MED’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MED’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 88, placing this stock worse than average.